Advance Program | ADA 82nd Scientific Sessions - 19

ADVANCE PROGRAM
* With the Eyes to Future-A 2022
View of DPN Opportunities
Beyond Cardio-Renal Benefits of
SGLT2i and GLP-RA-Why there are
No Neuropathy Outcomes Included in
Current Major Outcomes Trials?
Hertzel C. Gerstein, MD, MSc, FRCPC
Wearable and Neuropathy
Catherine Martin, MS, RN
Retinal Neurodegeneration-A
Window into Peripheral and Central
Nervous System Dysfunction
Simona Frontoni, MD
Question and Discussion Period
* Diabetes Care and Education
Specialists DCESs Value-Positive
Impact of DCESs on Therapeutic
Inertia
Overview of the Systematic Review-
Strategies for Overcoming Therapeutic
Inertia in Type 2 Diabetes
Christine A. Beebe, MS
Therapeutic Inertia-Models of Care
that Improve Outcomes
Shannon M. Knapps, BSN, RN, CDCES
Question and Discussion Period
* Physical Activity Lessons Learned
in DPP-Based Community
Translation Efforts to Prevent Type 2
Diabetes
Moving Towards Increasing Physical
Activity-Challenges, Successes, and
Potential Next Steps
Andrea Kriska, PhD
Increasing Movement through Sitting
Less-Does It Appear to Work?
Rachel G. Miller, PhD
Question and Discussion Period
* ADA Standards of Care 2022
Spotlight-Prevention or Delay of
Type 2 Diabetes and Associated
Comorbidities
ADA Standards of Care Professional
Practice Committee Process and
Overview
Florence M. Brown, MD
Individualizing Care Goals for Patients
at High Risk of Type 2 Diabetes
Vanita R. Aroda, MD
Behavior Change Interventions
Overview and Discussion
Gretchen Benson, RDN, LDN, CDCES
Pharmacotherapy Review and Updates
Scott Kahan, MD, MPH
The Bigger Picture in Prevention-
Access/Social Determinants of Health
and an Eye Towards Longer-Term Risks
(e.g., CV)
Jane E.B. Reusch, MD
Panel Discussion/Question and
Discussion Period
* Update on Monogenic and Neonatal
Diabetes
When to Screen and How to Manage
Monogenic Diabetes?
Siri Atma W. Greeley, MD, PhD
What's New in the Diagnosis and
Management of Monogenic Diabetes?
Jennifer Posey, MD, PhD
Question and Discussion Period
* Evolving Methods for Characterizing
Glycemic Control through
Continuous Glucose Monitoring
From Summary Statistics to Joint
Modeling-Evolution of Continuous
Glucose Monitoring Data Analyses
Kellee Miller, PhD
Functional Data Analyses to Account
for and Interpret Glucose Patterns in
Continuous Glucose Monitoring
Emrah Gecili, PhD
Joint Modelling of Glucose and Insulin
over Pregnancy to Account for Both
Average and Variability in Prediction of
a Large for Gestational Age Neonate
* Transplantation in the Time of
COVID-19
COVID-19 and Solid Organ
Transplantation-USA
Peter Chin-Hong, MD
COVID-19 and Solid Organ
Transplantation-The International
Perspective
Question and Discussion Period
* Not So Sweet? Low-Calorie
Sweeteners, Obesity and Metabolic
Health
Low-Calorie Sweetener Consumption,
Weight and Metabolic Health-What
we Know - and Don't
Physiological Effects of Low-Calorie
Sweeteners
Richard D. Mattes, MPH, PhD, RD
Question and Discussion Period
* Noninvasive Imaging of the Liver-
What Should You Understand, and
How Can You Help Your Patients
Noninvasive Liver Imaging Dystems
(MR, Ultrasound, etc)-What Are They
Really Telling You?
Mazen Noureddin, MD
Noninvasive Liver Imaging Systems-
How Do You Use That Information to
Care For Patients?
Cyrielle Caussy, MD, PhD
Question and Discussion Period
* Revisiting Hyperinsulinemia as the
Primary Defect in Type 2 Diabetes
Pathogenesis
Hyperinsulinemia Is the Primary Defect
James D. Johnson, PhD
Hyperinsulinemia Is Not the Primary
Defect
Steven E. Kahn, MB, ChB
Question and Discussion Period
2:00 p.m.-4:00 p.m.
* Mitigating ASCVD Risk in
Diabetes-Update in Mitigating
ASCVD Risk
What's the Role of Revascularization
in Patients with Diabetes and Chronic
Coronary Disease? Insights from
ISCHEMIA and ISCHEMIA-CKD
Sripal Bangalore, MD, MHA
GLP1-RA, Not SGLT2i, Should Be
the Preferred Antidiabetic Therapy for
Ischemic Stroke Prevention in Patients
with Diabetes
Liana K. Billings, MD, MMSc
Update on Prevention of Cardiovascular
Disease in Diabetes
Suzanne V. Arnold, MD, MHA
Question and Discussion Period
* Mitigating ASCVD Risk in
Diabetes-Role of Kidney in ASCVD
Impact of Kidney Disease on
Prescribing Drugs for ASCVD in
Patients with Diabetes
Joshua J. Neumiller, PharmD, CDE,
FAADE, FASCP
Choice of Renal Endpoints in DKD
Trials-Hard Renal Outcomes or
Validated Surrogates?
Julia Scialla, MD
Updated Guidelines on BP Control for
Patients with Diabetes and CKD
Alfred K. Cheung, MD
Question and Discussion Period
HYBRID | NEW ORLEANS | JUNE 3-7, 2022 | #ADA2022
Speakers and presentation titles are subject to change.
19

Advance Program | ADA 82nd Scientific Sessions

Table of Contents for the Digital Edition of Advance Program | ADA 82nd Scientific Sessions

Advance Program | ADA 82nd Scientific Sessions - 1
Advance Program | ADA 82nd Scientific Sessions - 2
Advance Program | ADA 82nd Scientific Sessions - 3
Advance Program | ADA 82nd Scientific Sessions - 4
Advance Program | ADA 82nd Scientific Sessions - 5
Advance Program | ADA 82nd Scientific Sessions - 6
Advance Program | ADA 82nd Scientific Sessions - 7
Advance Program | ADA 82nd Scientific Sessions - 8
Advance Program | ADA 82nd Scientific Sessions - 9
Advance Program | ADA 82nd Scientific Sessions - 10
Advance Program | ADA 82nd Scientific Sessions - 11
Advance Program | ADA 82nd Scientific Sessions - 12
Advance Program | ADA 82nd Scientific Sessions - 13
Advance Program | ADA 82nd Scientific Sessions - 14
Advance Program | ADA 82nd Scientific Sessions - 15
Advance Program | ADA 82nd Scientific Sessions - 16
Advance Program | ADA 82nd Scientific Sessions - 17
Advance Program | ADA 82nd Scientific Sessions - 18
Advance Program | ADA 82nd Scientific Sessions - 19
Advance Program | ADA 82nd Scientific Sessions - 20
Advance Program | ADA 82nd Scientific Sessions - 21
Advance Program | ADA 82nd Scientific Sessions - 22
Advance Program | ADA 82nd Scientific Sessions - 23
Advance Program | ADA 82nd Scientific Sessions - 24
Advance Program | ADA 82nd Scientific Sessions - 25
Advance Program | ADA 82nd Scientific Sessions - 26
Advance Program | ADA 82nd Scientific Sessions - 27
Advance Program | ADA 82nd Scientific Sessions - 28
Advance Program | ADA 82nd Scientific Sessions - 29
Advance Program | ADA 82nd Scientific Sessions - 30
Advance Program | ADA 82nd Scientific Sessions - 31
Advance Program | ADA 82nd Scientific Sessions - 32
https://www.nxtbookmedia.com